Characterization of recent non-fentanyl synthetic opioids via three different in vitro µ-opioid receptor activation assays
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
New synthetic opioids (NSOs) are one of the fastest growing groups of new psychoactive substances. Amid this dynamic landscape, insight into the pharmacology of NSOs is important to estimate the harm potential of newly emerging drugs. In this work, we determined the µ-opioid receptor (MOR) affinity and activation potential of seven poorly characterized non-fentanyl NSOs (N-ethyl-U-47700, 3,4-difluoro-U-47700, U-47931E/bromadoline, 2,4-difluoro-U-48800, U-62066/spiradoline, 2F-viminol, ketobemidone) and a panel of nine reference opioids. MOR affinity was determined via [3H]-DAMGO binding in rat brain tissue homogenates, and was found to correlate well with different functional parameters. MOR activation potential was studied at different levels of receptor signaling using three distinct assays (NanoBiT® MOR-β-arrestin2/mini-Gαi and AequoScreen®). The most active compounds were ketobemidone (EC50 32.8–528 nM; Emax 105–271%, relative to hydromorphone) and N-ethyl-U-47700 (EC50 241–767 nM; Emax 139–247%). The same opioids showed the strongest MOR affinity. As most of the other NSOs only weakly activated MOR in the three assays (EC50 values in the high nM–µM range), they likely do not pose a high overdose risk. 2F-viminol (EC50 2.2–4.5 µM; Emax 21.2–61.5%) and U-47931E/bromadoline (EC50 0.55–2.9 µM; Emax 52.8–85.9%) were partial agonists compared to hydromorphone, and maximum receptor activation was not reached for 2,4-difluoro-U-48800 (EC50 > 22 µM). We further highlight the importance of considering specific assay characteristics upon interpretation of potencies, efficacies and biased agonism. As absolute values may greatly differ between assays with varying experimental set-ups, a comparison of functional parameters to those of well-characterized reference agonists is considered the most informative.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Waldhoer, M., Bartlett, S. E., & Whistler, J. L. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073940 · Cited by 740 · cited 2×
“While it is known that MOR is predominantly coupled to the Gαi/o protein subtype, interactions with other G proteins have also been described, further diversifying intracellular signaling (Connor and Christie 1999; Waldhoer et al. 2004).”
BackgroundUniform assessment and ranking of opioid Mu receptor binding constants for selected opioid drugs
Volpe, D. A., Tobin, G. A. M., Mellon, R. D., Katki, A. G., Parker, R. J., Colatsky, T., Kropp, T. J., & Verbois, S. L. (2011) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2010.12.007 · Cited by 446
Untangling the complexity of opioid receptor function
Valentino, R. J., & Volkow, N. D. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0225-3 · Cited by 383
kappa-Opioid receptor signaling and brain reward function
Bruijnzeel, A. W. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.09.008 · Cited by 214 · cited 1×
“Furthermore, the abuse potential of kappa-opioid agonists could be limited by adverse effects (i.e., dysphoria) (Bruijnzeel 2009; Brust et al.”
BackgroundVandeputte, M. M., Van Uytfanghe, K., Layle, N. K., St. Germaine, D. M., Iula, D. M., & Stove, C. P. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00064 · Cited by 161
Self-citationBaumann, M. H., Majumdar, S., Le Rouzic, V., Hunkele, A., Uprety, R., Huang, X. P., Xu, J., Roth, B. L., Pan, Y.-X., & Pasternak, G. W. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.08.016 · Cited by 92
Vasudevan, L., Vandeputte, M., Deventer, M., Wouters, E., Cannaert, A., & Stove, C. P. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113910 · Cited by 55
First Report on Brorphine: The Next Opioid on the Deadly New Psychoactive Substance Horizon?
Verougstraete, N., Vandeputte, M. M., Lyphout, C., Cannaert, A., Hulpia, F., Van Calenbergh, S., Verstraete, A. G., & Stove, C. (2021) · Journal of Analytical Toxicology · doi:10.1093/jat/bkaa094 · Cited by 44
Self-citationBlanckaert, P., Balcaen, M., Vanhee, C., Risseeuw, M., Canfyn, M., Desmedt, B., Van Calenbergh, S., & Deconinck, E. (2021) · Drug Testing and Analysis · doi:10.1002/dta.3113 · Cited by 39
Cited by
De Vrieze, L. M., Walton, S. E., Pottie, E., Papsun, D., Logan, B. K., Krotulski, A. J., Stove, C. P., & Vandeputte, M. M. (2024) · Archives of Toxicology · doi:10.1007/s00204-024-03774-7 · Cited by 58
“C ) allowed a comparative assessment of potencies (Vandeputte et al. 2022c) that was highly similar between both assays.”
ResultSelf-citationNon-Fentanyl New Synthetic Opioids—An Update
Zawilska, J. B., Adamowicz, P., Kurpeta, M., & Wojcieszak, J. (2023) · Forensic Science International · doi:10.1016/j.forsciint.2023.111775 · Cited by 55
Vandeputte, M. M., Tsai, M.-H. M., Chen, L., Glatfelter, G. C., Walther, D., Stove, C. P., Shi, L., & Baumann, M. H. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.109939 · Cited by 39
Self-citationMonti, M. C., De Vrieze, L. M., Vandeputte, M. M., Persson, M., Gréen, H., Stove, C. P., & Schlotterbeck, G. (2024) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2024.116453 · Cited by 18
Self-citationVandeputte, M. M., Bilel, S., Tirri, M., Corli, G., Bassi, M., Layle, N. K., Fantinati, A., Walther, D., Iula, D. M., Baumann, M. H., et al. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110113 · Cited by 19
Self-citation
Metadata
- Authors
- Vandeputte, M. M., Persson, M., Walther, D., Vikingsson, S., Kronstrand, R., Baumann, M. H., Gréen, H., & Stove, C. P.
- Venue
- Archives of Toxicology
- Published
- 2022-01-24
- Volume
- 96
- Issue
- 3
- Pages
- 877-897
- ISSN
- 0340-5761 (ISSN-L)
- 1432-0738
- OpenAlex
- W4207045874
- Cited by
- 24
- References
- 9
- FWCI
- 12.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Characterization of recent non-fentanyl synthetic opioids via three different in vitro µ-opioid receptor activation assays. https://app.cochat.ai/papers/10.1007/s00204-021-03207-9
- The paper
- Vandeputte, M. M., Persson, M., Walther, D., Vikingsson, S., Kronstrand, R., Baumann, M. H., Gréen, H., & Stove, C. P. (2022). Characterization of recent non-fentanyl synthetic opioids via three different in vitro µ-opioid receptor activation assays. Archives of Toxicology. https://doi.org/10.1007/s00204-021-03207-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.